Effects of high‐intensity statin therapy on steroid hormones and vitamin D in type 2 diabetic men: A prospective self‐controlled study

Abstract

AbstractThe study aimed to assess the effect of high‐intensity statin therapy on testicular and adrenal steroids and vitamin D levels in type 2 diabetic men. A prospective study, conducted between March 2021 and July 2022, including 60 men with type 2 diabetes, aged 40–65 years, statin‐free, and in whom treatment with high‐intensity statin was indicated. The patients had two visits, before and 6 months after a daily intake of 40 mg of atorvastatin. During each visit, they underwent a clinical examination, and a fasting blood sample was collected for biological and hormonal measurements. There was a significant increase in the prevalence of decreased libido (from 22% to 47%, p = 0.001) and a significant decrease in the frequency of sexual intercourse (from 4 [1–8] to 3 [0–4] per month, p = 0.005). The median ADAM's score significantly increased (from 4 [2–7] to 6 [3–8], p = 0.000). Twenty‐two percent of the patients developed gynecomastia. The median total, bioavailable and free testosterone significantly decreased from 15.1 (11.4–17.4), 6.3 (5.0–7.8), and 0.27 (0.22–0.33) nmol/L to 12.7 (10.7–15.9), 5.7 (4.4–7.0), and 0.24 (0.19–0.30) nmol/L, respectively, with no change in FSH and LH levels. Three patients (5%) developed hypogonadism (testosterone <8 nmol/L). There was a significant decrease in DHEAS from 4.5 (2.8–6.1) to 3.8 μmol/L (2.6–5.6) and no change in cortisol and vitamin D levels. High‐intensity statin therapy decreased androgen levels in type 2 diabetic men with significant clinical impact.